Stay updated on Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.

Latest updates to the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page
- Check6 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page now displays a 403 Forbidden error for the study record, replacing the previous detailed content. Sponsor-related materials and links to study documents have been removed.SummaryDifference18%

- Check27 days agoChange DetectedRevision tag updated from v3.6.6 to v3.7.0 on the page, signaling a new document revision. It appears to be a metadata/versioning update rather than a substantive change to study content.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5. This indicates a new version of the page rendering, applied as a maintenance or QA update without altering study details or user interactions.SummaryDifference0.0%

- Check48 days agoChange DetectedA new line '2017 ( U.S. NIH Grant/Contract )' was added under Other Study ID Numbers, providing an additional funding identifier for the trial. This addition supplies extra context about funding but does not modify the study's primary data.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, indicating a new version of the page's documentation/template. This update records a small adjustment to the page's revision history.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.